BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (ROIV) today announced positive results from the induction period of the TUSCANY-2 Phase 2b ...

Investigator-initiated data from Houston Methodist Hospital showed LD IL-2 reduced proinflammatory factors, both systemically and within the central nervous system, while demonstrating statistically ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, ...

Full results published in the New England Journal of Medicine and presented at ATS 2025 International Conference BATURA builds upon the previous Phase III MANDALA and DENALI trials and in totality, ...

Twice-yearly inclisiran (Leqvio) monotherapy showed clinically meaningful and statistically significant LDL-C lowering in patients at low or moderate risk of atherosclerotic cardiovascular disease in ...

Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial Nivolumab plus relatlimab ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...

Researchers in China have found no statistically significant advantage for infrapatellar fat pad glucocorticoid injection ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.